J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

Cosentyx was the first IL-17 inhibitor to reach the market and, while it has since been joined by rivals from Eli Lilly (Taltz) and Valeant (Siliq), is well ahead in

Daily Brief: Andrew Witty's replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

Valeant shares tumble after FDA rejection. A rejection by the US regulator for Valeant’s plaque psoriasis treatment. ... Valeant said in a statement that the FDA had not specified any clinical efficacy or safety shortcomings in its Complete Response

UK, Germany back routine use of J&J’s Tremfya

Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for psoriasis is looking increasingly crowded, and a lot will depend on which of the

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

Looking to distance itself from toxic past, Valeant to rebrand as Bausch Health. ... Valeant’s years of buccaneering mergers and acquisitions, suspect business practices and allegations of fraud have left it saddled with debt and a pariah-like status

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]